Clinical Thought Leadership
Latest
-
![]()
Educational Articles
-
![Official announcements from Cizzle Bio regarding new products, strategic partnerships, financial reports, and other corporate communications.]()
Press Releases
-
![Updates on company milestones, industry news, collaborations, partnerships, and significant events related to Cizzle Bio and its impact on the biotechnology field.]()
News
-
![Detailed scientific studies and findings related to lung cancer detection, biomarker research, and other relevant medical research conducted or published by Cizzle Bio or related entities.]()
Research Papers
Clinical Thought Leadership Articles
Explore expert perspectives from leading physicians, researchers, and oncology specialists on the evolving role of biomarker-based technologies in cancer diagnostics. This series highlights clinical insights on early detection, diagnostic innovation, and real-world applications that are shaping the future of patient care.
The Power of Early Detection and the Promise of the CIZ1B Biomarker Blood Test for Lung Cancer—A Leading Oncologist’s Perspective
Dr. Jessica Trevino Jones, a leading oncologist at UT Health San Antonio MD Anderson, highlights the promise of Cizzle Bio’s CIZ1B biomarker blood test in changing the future of lung cancer detection and prevention.
Advancing Early Detection of Lung Cancer – Moffitt Cancer Center’s Clinical Trial of the CIZ1B Biomarker-Based Blood Test
A new clinical trial at Moffitt Cancer Center is evaluating the CIZ1B biomarker blood test—an early-detection tool with potential to improve lung cancer diagnosis and long-term monitoring.
Dr. Jessica Trevino Jones, a leading oncologist at UT Health San Antonio MD Anderson, highlights the promise of Cizzle Bio’s CIZ1B biomarker blood test in changing the future of lung cancer detection and prevention.